We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.14%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.52B
AUM Growth
+$385M
Cap. Flow
+$3.2M
Cap. Flow %
0.04%
Top 10 Hldgs %
34.42%
Holding
155
New
17
Increased
44
Reduced
30
Closed
23

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$102M
2
CFN
CAREFUSION CORPORATION
CFN
+$68.7M
3
BMY icon
Bristol-Myers Squibb
BMY
+$60.2M
4
SHPG
Shire pic
SHPG
+$55.3M
5
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$54M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$146M
2
AGN
Allergan Inc
AGN
+$113M
3
PRTA icon
Prothena Corp
PRTA
+$72.4M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$63M
5
XLRN
Acceleron Pharma
XLRN
+$56.7M

Sector Composition

Rank Sector Weight
1 Healthcare 82.59%
2 Financials 0.08%
3 Technology 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
51
Celldex Therapeutics
CLDX
$2.81B
$35.6M 0.42%
145,440
-11,067
-7% -$2.5M
XTNT icon
52
Xtant Medical Holdings
XTNT
$59.1M
$32.1M 0.38%
39,620
– –
DRTX
53
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
$30.4M 0.36%
1,785,714
– –
EXAS
54
DELISTED
Exact Sciences
EXAS
$29.3M 0.34%
1,723,000
-170,000
-9% -$2.34M
ARRY
55
DELISTED
Array Biopharma Inc
ARRY
$29.2M 0.34%
6,402,800
+105,800
+2% +$438K
MDT icon
56
Medtronic
MDT
$113B
$27M 0.32%
423,300
+100,300
+31% +$6.09M
XNPT
57
DELISTED
XENOPORT, INC.
XNPT
$26.8M 0.31%
5,546,100
– –
LLY icon
58
Eli Lilly
LLY
$1.09T
$24.9M 0.29%
400,000
-143,000
-26% -$8.53M
MRTX
59
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$23.4M 0.28%
1,172,000
-102,332
-8% -$1.98M
JAZZ icon
60
CALL
Jazz Pharmaceuticals
JAZZ
$16.1B
$22.1M 0.26%
+150,000
New +$20.8M
ALKS icon
61
Alkermes
ALKS
$8.09B
$21.8M 0.26%
+433,300
New +$20M
QGENF
62
DELISTED
QIAGEN NV
QGENF
$19.1M 0.22%
+781,400
New +$19.1M
CAH icon
63
Cardinal Health
CAH
$54.6B
$19M 0.22%
277,000
+10,000
+4% +$681K
NPSP
64
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$18.2M 0.21%
+550,200
New +$15.9M
CERS icon
65
Cerus
CERS
$577M
$17.6M 0.21%
4,238,000
– –
BHC icon
66
Bausch Health
BHC
$1.7B
$17.4M 0.2%
138,000
+5,000
+4% +$638K
JAZZ icon
67
Jazz Pharmaceuticals
JAZZ
$16.1B
$16.9M 0.2%
115,000
– –
FPRX
68
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$16.7M 0.2%
1,075,400
– –
COV
69
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$16.3M 0.19%
+180,600
New +$13.5M
PBYI icon
70
Puma Biotechnology
PBYI
$398M
$14.4M 0.17%
+218,100
New +$15.5M
LITS
71
Lite Strategy Inc
LITS
$32.5M
$12.2M 0.14%
96,225
– –
GEVA
72
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$11.6M 0.14%
111,100
– –
QCOR
73
DELISTED
QUESTCOR PHARMA INC
QCOR
$11.6M 0.14%
125,000
+45,000
+56% +$3.85M
QCOR
74
PUT
DELISTED
QUESTCOR PHARMA INC
QCOR
$11.6M 0.14%
+125,000
New +$10.7M
AGEN
75
Agenus
AGEN
$275M
$11.5M 0.14%
182,712
-74,586
-29% -$4.32M
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2014 Portfolio in Review

As of Q2 2014, OrbiMed held 155 positions worth $8.52B, up 4.7% from $8.13B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q2 2014 filing shows 17 new, 44 increased, 30 reduced and 23 closed positions. Its largest new stake was Alkermes: 433,300 shares worth $21.8M. The largest sale was Gilead Sciences, an estimated $146M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 83% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q2 2014 buy was Alkermes: 433,300 shares worth $21.8M.
  • OrbiMed added most to Ironwood Pharmaceuticals in Q2 2014, an estimated $102M increase.
  • OrbiMed's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $146M.
  • OrbiMed fully exited Prothena Corp in Q2 2014, selling an estimated $72.4M.
  • OrbiMed's ten largest holdings make up 34% of its $8.52B portfolio in Q2 2014.
  • OrbiMed opened 17 new positions and closed 23 in Q2 2014.
  • OrbiMed's portfolio value rose 4.7% quarter-over-quarter to $8.52B.

Based on OrbiMed's 13F filing for Q2 2014, filed 14 Aug 2014.